Comparative Pharmacology
Head-to-head clinical analysis: DIONOSIL AQUEOUS versus MD 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIONOSIL AQUEOUS versus MD 50.
DIONOSIL AQUEOUS vs MD-50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DIONOSIL AQUEOUS contains propyliodone, a radiocontrast agent that absorbs X-rays, providing visualization of bronchial structures. It acts by coating the bronchial mucosa and filling the airways, allowing radiographic imaging.
Iodinated radiographic contrast agent that attenuates X-rays due to its high iodine content, allowing visualization of vascular structures and organs during imaging. It distributes into the extracellular fluid compartment and is excreted unchanged by glomerular filtration.
Intra-articular injection: 2-3 mL of 1% solution (20-30 mg) per joint; maximum 4 joints per session. Intravenous: 2-4 mL of 20% solution (400-800 mg) diluted in 20 mL water, administered slowly over 5-10 minutes, for peripheral angiography.
300 mg intravenously every 12 hours.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours in patients with normal renal function; prolonged in renal impairment.
Terminal elimination half-life is 2.5-3.0 hours (normal renal function). In patients with renal impairment (CrCl <30 mL/min), half-life may be prolonged up to 24-36 hours, necessitating dose adjustment. For contrast media, the half-life determines the window for imaging procedures.
Renal excretion of unchanged drug accounts for >95% of elimination; <5% is eliminated via biliary/fecal routes.
Primarily renal excretion of unchanged drug (90-95%) via glomerular filtration; minimal biliary/fecal elimination (<5%).
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent